McConaghy acquires Cure Marine, bringing performance catamarans in-house

McConaghy has turned what started as a possible production partnership into a full takeover of Cure Marine’s brand and intellectual property, bringing one of Australia’s better-known performance-catamaran names into its own manufacturing system.

That matters because this is not just a logo swap. Cure Marine has ended its life as an independent builder, but the Cure range is set to continue under McConaghy’s composite engineering, autoclave technology and larger production footprint. In practical terms, the design lineage stays alive while the industrial platform underneath it changes completely. For buyers, that can mean more consistent build access, stronger backing for the model line and, if McConaghy executes, a wider international reach without losing the Australian performance-cat identity that made Cure relevant in the first place.

McConaghy said it was already working on an evolution of the Cure 55GT and Cure 48GT, with refinements due later in the month. That is the detail current and prospective owners will watch most closely. If the changes stay true to the original formula, the boats could gain from McConaghy’s scale and engineering depth without blurring into a generic portfolio piece. If the updates lean too far toward standardization, Cure risks becoming another badge on a bigger builder’s shelf instead of a distinct performance brand with its own voice.

To steady the transition on the commercial side, McConaghy appointed Ed Penn as sales manager for the Cure series. Penn’s previous role in Cure’s early success gives the handover some continuity at exactly the point where owners, brokers and new buyers will be looking for reassurance on production timing, specification changes and what happens to factory support. In a niche segment like high-performance multihulls, that kind of continuity can matter as much as the carbon layup.

Mark Evans, McConaghy’s group managing director, framed the acquisition as a way to fold a successful Australian design into McConaghy’s fold while giving it a stronger future. The company also pushed the deal into the market immediately, inviting interested buyers and media to meet the team at the International Multihull Show in La Grande Motte, where production slots could be discussed. For anyone tracking the performance-cat market, this was a clear consolidation play: fewer moving parts, a bigger industrial base and a better shot at taking Cure beyond its original footprint without losing the sharp-edged identity that made it worth buying in the first place.